AKT1 and cancer: Although data on the differential responses between PI3K/Akt/mTOR and MAPK/ERK signalling following statins treatment in cancer are very limited, sensitivity to inhibitors of these two signalling pathways has been linked to genetic mutations in key element in these pathways, such as PIK3CA, PTEN, Akt and Raf [36, 37].